Advertisement

Pharmacy World and Science

, Volume 15, Issue 3, pp 98–104 | Cite as

Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans

  • T. B. Vree
  • M. van den Biggelaar-Martea
  • E. W. J. van Ewijk-Beneken Kolmer
  • Y. A. Hekster
Articles

Abstract

A gradient reversed-phase high pressure liquid chromatographic analysis was developed for the direct measurement of nalidixic acid with its acyl glucuronide, 7-hydroxymethylnalidixic acid with its acyl and ether glucuronides, and 7-carboxynalidixic acid in human plasma and urine. The glucuronides and 7-carboxynalidixic acid were not present in plasma after an oral dose of 1,000 mg nalidixic acid. The acyl glucuronides of 7-carboxynalidixic acid were not present in plasma and urine. The acyl glucuronides are stable in urine at pH 5.0–5.5. The subject's urine must therefore be acidified by the oral intake of 4×1 g of ammonium chloride per day. With acidic urine, hardly any nalidixic acid was excreted unchanged (0.2%). It was excreted as acyl glucuronide (53.4% of dose), 7-hydroxymethylnalidixic acid (10.0%), the latter's acyl glucuronide (30.9%), and 7-carboxynalidixic acid (4.2%).

Keywords

Chromatography, high pressure liquid Glucuronates Metabolites Nalidixic acid Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ferry N, Cuisinaud G, Pozet N, Zech PY, Sassard J. Nalidixic acid kinetics after single and repeated oral doses. Clin Pharmacol Ther 1981;29:695–8.PubMedGoogle Scholar
  2. 2.
    Cuisinaud G, Ferry N, Seccia M, Bernard N, Sassard J. Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed phase high performance liquid chromatography. J Chromatogr/Biomed Appl 1980;181:399–406.Google Scholar
  3. 3.
    Cuisinaud G, Ferry N, Pozet N, Zech PY, Sassard J. Nalidixic acid kinetics in renal insufficiency. Br J Clin Pharmacol 1982;14:489–93.PubMedGoogle Scholar
  4. 4.
    Ferry N, Cuisinaud G, Pozet N, Zech PY, Sassard J. Influence du probénécide sur la pharmacocinétique de l'acide nalidixique. Therapie 1982;37:645–9.PubMedGoogle Scholar
  5. 5.
    Ferry N, Cuisinaud G, Sassard J. Pharmacokinetics of nalidixic acid associated with sodium citrate. Biopharm Drug Dispos 1984;5:211–8.PubMedGoogle Scholar
  6. 6.
    Vree TB, Wijnands WJA, Baars AM, Hekster YA. Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation. Pharm Weekbl [Sci] 1988;10:193–9.Google Scholar
  7. 7.
    McChesney EW, Froelich EJ, Lesher GY, Grain AVR, Rosi D. Absorption, excretion and metabolism of a new antibacterial agent nalidixic acid. Toxicol Appl Pharmacol 1964;6:292–309.Google Scholar
  8. 8.
    Portmann GA, McChesney EW, Stander H, Moore WE. Pharmacokinetic model for nalidixic acid in man II. Parameters for absorption, metabolism and elimination. J Pharm Sci 1966;55:72–8.PubMedGoogle Scholar
  9. 9.
    Männistö PT. Pharmacokinetics of nalidixic acid and oxolinic acid in healthy women. Clin Pharmacol Ther 1976;19:37–46.PubMedGoogle Scholar
  10. 10.
    Graber H, Perényi T, Ludwig E, Arr M. The human biotransformation of nalidixic acid. Int J Clin Pharmacol Biopharm 1976;13:76–82.PubMedGoogle Scholar
  11. 11.
    Eggers NJ, Doust K. Isolation and identification of probenecid acyl glucuronide. J Pharm Pharmacol 1981;33:123–4.PubMedGoogle Scholar
  12. 12.
    Faed EM. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab Rev 1984;15:1213–49.PubMedGoogle Scholar
  13. 13.
    Smith PC, Hasegawa J, Langendijk PNJ, Benet LZ. Stability of acyl glucuronides in blood, plasma and urine. Studies with zomepirac. Drug Metab Dispos 1985;13:110–2.PubMedGoogle Scholar
  14. 14.
    Brühl P, Gundlach G, Wintjes K, Eicher W, Bastian HP. Neue Untersuchungen zur Pharmacokinetik der Nalidixinsäure. Arzneimittelforsch 1973;23:1311–3.PubMedGoogle Scholar
  15. 15.
    Portmann GA, McChesney EW, Stander H, Moore WE. Pharmacokinetic model for nalidixic acid in man I. Kinetic pathways for hydroxynalidixic acid. J Pharm Sci 1966;55:59–62.PubMedGoogle Scholar
  16. 16.
    Sorel RHA, Hulshoff A, Snelleman C. High-performance chromatographic analysis of nalidixic acid and hydroxynalidixic acid in plasma with a dynamic anion-exchange system. J Chromatogr/Biomed Appl 1980;221:129–37.Google Scholar
  17. 17.
    Vree TB, Beneken Kolmer EWJ, Martea M, Bosch R, Hekster YA, Shimoda M. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfadimethoxine in humans. Pharm Weekbl [Sci] 1990;12:71–5.Google Scholar
  18. 18.
    Vree TB, Beneken Kolmer EWJ, Martea M, Bosch R, Shimoda M. High-performance liquid chromatography of sulphadimethoxine and its N1-glucuronide, N4-acetyl and N4-acetyl-N1-glucuronide metabolites in human plasma and urine. J Chromatogr/Biomed Appl 1990;526:119–28.Google Scholar
  19. 19.
    Vree TB, Beneken Kolmer EWJ, Hekster YA, Shimoda M, Ono M, Miura T. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfa-6-monomethoxine in humans. Drug Metab Dispos 1990; 18:852–8.PubMedGoogle Scholar
  20. 20.
    Vree TB, Beneken Kolmer EWJ, Hekster YA. High pressure liquid chromatographic analysis and preliminary pharmacokinetics of sulfaphenazole and its N2-glucuronide and N4-acyl metabolites in plasma and urine of man. Pharm Weekbl [Sci] 1990;12:243–7.Google Scholar
  21. 21.
    Vree TB, Steegers-Theunissen RPM, Baars AM, Hekster YA. Direct high-performance liquid chromatographic analysis of p-hydroxyphenyl-phenylhydantoin glucuronide, the final metabolite of phenytoin, in human serum and urine. J Chromatogr/Biomed Appl 1990;526:581–9.Google Scholar
  22. 22.
    Vree TB, Baars AM, Wuis EW. Direct high-performance liquid chromatographic analysis and preliminary pharmacokinetics of enantiomers of oxazepam and temazepam with their corresponding glucuronide conjugates. Pharm Weekbl [Sci] 1991;13:83–91.Google Scholar
  23. 23.
    Vree TB, Martea M, Lewin LM. High-performance liquid chromatography of sulfapyridine and its acetyl and glucuronide metabolites in rat and human urine. J Chromatogr/ Biomed Appl 1991;534:214–22.Google Scholar
  24. 24.
    Vree TB, Beneken Kolmer EWJ, Hekster YA. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfamethomidine in humans. Pharm Weekbl [Sci] 1991;13:198–206.Google Scholar
  25. 25.
    Vree TB, Beneken Kolmer EWJ. Direct measurement of probenecid and its glucuronide conjugate by means of high performance liquid chromatography in plasma and urine of humans. Pharm Weekbl [Sci] 1992;14:83–7.Google Scholar
  26. 26.
    Vree TB, Beneken Kolmer EWJ, Wuis EW, Hekster YA. Capacity limited renal glucuronidation of probenecid by humans. A pilotV max-finding study. Pharm Weekbl [Sci] 1992;14:325–32.Google Scholar
  27. 27.
    Vree TB, Van den Biggelaar-Martea M, Verwey-van Wissen CPWGM. Determination of naproxen and its metaboliteO-desmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient HPLC analysis. J Chromatogr/Biomed Appl 1992;578:239–49.Google Scholar
  28. 28.
    Vree TB, Van Ewijk-Beneken Kolmer EWJ, Nouws JFM. Direct gradient HPLC analysis and preliminary pharmacokinetics of flumequine and flumequine acyl glucuronide in humans. Effect of probenecid. J Chromatogr/Biomed Appl 1992;579: 131–41.Google Scholar

Copyright information

© Royal Dutch Association for the Advancement of Pharmacy 1993

Authors and Affiliations

  • T. B. Vree
    • 2
  • M. van den Biggelaar-Martea
    • 1
  • E. W. J. van Ewijk-Beneken Kolmer
    • 1
  • Y. A. Hekster
    • 1
  1. 1.Department of Clinical PharmacyAcademic Hospital Nijmegen Sint Radboud, University of NijmegenGA Nijmegenthe Netherlands
  2. 2.Institute of AnaesthesiologyAcademic Hospital Nijmegen Sint Radboudthe Netherlands

Personalised recommendations